Top ▲
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
Checkpoint proteins include co-inhibitory and co-stimulatory receptors on immune effectors cells. Blocking monoclonal antibodies (mAbs) to co-inhibitory receptors such as PD-1 and CTLA4 have sucessfully entered clinical practice as cancer immunotherapies. Co-stimulatory receptors such as GITR, ICOS and OX40 are being targeted by immunostimulatory mAbs in preclinical and clinical development programmes [3,13].
SIGLEC2 (CD22)
Show summary »
More detailed page |
SIGLEC3 (CD33)
C
Show summary »
More detailed page |
CD80
C
Show summary »
More detailed page |
LILRB1 (leukocyte immunoglobulin like receptor B1 (CD85j))
Show summary »
More detailed page |
CD86
C
Show summary »
More detailed page |
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 (CD152))
C
Show summary »
More detailed page |
LAG3 (CD223) / CD223
Show summary »
More detailed page |
B7-H3 (CD276)
Show summary »
More detailed page |
ICOS (CD278)
Show summary »
More detailed page |
PD-1 (programmed cell death 1 (CD279))
C
Show summary »
More detailed page |
TIM3 (CD366)
Show summary »
More detailed page |
ILDR2 (immunoglobulin like domain containing receptor 2)
Show summary »
More detailed page |
PVRIG (PVR related immunoglobulin domain containing)
Show summary »
More detailed page |
VISTA (V-set immunoregulatory receptor)
Show summary »
More detailed page |
Database page citation:
Other immune checkpoint proteins. Accessed on 04/12/2023. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=949.
Concise Guide to PHARMACOLOGY citation:
Alexander SP, Kelly E, Mathie A, Peters JA, Veale EL et al. (2021) THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. Br J Pharmacol. 178 Suppl 1:S1-S26.